Nominate your peers and colleagues for HFSA Awards through February 27!
2023 | HFSA

Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

Industry News In The News

Oak Ridge, TN – January 3, 2023 — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic pressure (PADP) monitor – two key metrics of cardiovascular congestion.  Pressures, as a proxy measure, are sometimes used in guiding volume management decisions by clinicians.  Data from the study demonstrated a lack of correlation between pressure measures and actual blood volume, highlighting the need for direct and 98% accurate volume measurement that the BVA-100 blood test provides.

The study titled, “Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes,” assessed the relationship between cardiac filling pressures (a commonly used surrogate to assess blood volume) and total blood volume (TBV) measurement using Daxor’s BVA-100 blood test between sexes and left ventricular ejection fraction (LVEF), key clinical determinants of response to therapy and outcomes in heart failure. 

The study results showed there was no significant difference between PADP and TBV between sexes and consistent lack of correlation between PADP and TBV.  Veraprapas Kittipibul, M.D., lead investigator of the study, concluded, “The two key metrics of cardiovascular congestion, namely, intracardiac pressure and intravascular volume, were disassociated across both sexes and LVEF.  Knowledge of unique pressure-volume profiles perhaps demands for distinct approaches to decongestion strategies.”